Instituto Nacional de Câncer (Brasil). Plano de ação para redução da incidência e mortalidade por câncer do colo do útero -Rio 
RESULTS
Annual direct cost of cervical cancer was estimated in BRL 68 million, as BRL 44.6 million (65%) refer to ambulatorial cost and BRL 23.7 million (35%) to hospital bills (Table 1 ). An average of 10.885 patients have ambulatory assistance, correspondent to 94.754 high complexity procedure authorisations (HCPAs). Also, 10.244 patients are hospitalised annually, total of 14.169 authorised hospital admissions (AHA), an average of 1.4 admissions per patient/year. 
BACKGROUND
Cervical cancer (CC) is the third most common type of cancer among the feminine population, and the fourth cause of death in women by cancer in Brazil, 1,2 affecting young women with average age of 49 years-old. 3 According to the National Institute of Cancer (INCA) 15,590 new cases of cervical cancer were expected in Brazil in 2014. Compared to developed countries, the incidence is twice higher in underdeveloped countries. 4
The main strategy for cervical cancer control in Brazil is population screening by performing conventional cytopathological test (Pap smear) in women from 25 to 64 years-old. 5 Recently, the Ministry of Health started to offer anti-HPV vaccine to Brazilian girls from 9 to 13 years-old, however, any impact on CC incidence and mortality will only occur 20 years from now. 6
As a public health problem, the management of CC generates significant annual expenditures. The nature of disease favors the implementation of preventive strategies; however the profile of patients reveals issues in access to healthcare services by patients with a socio-economic exclusion profile at high risk for cervical cancer. 7
The economic burden of CC includes both direct costs and indirect costs to the patient and/or their families. The level of indirect economic burden will vary depending on several factors; e.g. productivity and future earnings, access to reimbursed treatment and debts resulting from loss of income. Indirect economic burden is particularly notable in CC patients as they are often diagnosed and treated during the period of their working lives. 
CONCLUSIONS
The results reveal that the cervical cancer cost is high in Brazil, especially because most part of cases affect women in working age. In spite of major efforts, CC is still a high impact disease and requires a comprehensive approach including community mobilization and education, prevention, screening, diagnosis and treatment, to address needs of both healthy women and CC patients irrespectively of disease stage. Despite these presented results are an approximation of the real costs of illness, it can be a useful data to improve health management and public policies.
METHODS
The total cervical cancer social cost was calculated including direct medical costs (outpatient and inpatient), nonmedical costs (caregiver day hospital), productivity loss due to inability of the patient to work, potential lifeyears lost and income loss due to premature death. Annual medical and nonmedical costs were extracted from Brazilian official database (DATASUS) based on the average annual costs of the last three years (2012 2014). Inpatient productivity loss was calculated considering the mean length of stay reported in DATASUS and the Brazilian minimum wage. Outpatient productivity loss was calculated considering that patient would take one to fifteen days off. Income loss due to premature death was measured subtracting the Brazilian life expectancy by the age of death, also reported in DATASUS, and multiplying by the Brazilian annual average wage reported by Brazilian Institute of Geography and Statistics. International Classification of Diseases (ICD10) codes considered in this analysis were C358 and C359. Table 2 presents outpatient and inpatient costs segmented by region. It is noted that results are coherrent among regions, only the north region has a larger proportion of outpatient assistance (77%) in comparison to the brazilian average (65%). 
